Avastin versus Lucentis: ethical issues in treatment of age-related macular degeneration.
Klein
Richard M
RM
Klein
Ronnie Boriskin
RB
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D026690:Ethics, Clinical; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D010817:Physician-Patient Relations / Q000941:ethics*; D000069579:Ranibizumab; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab